SeqOne, a Montpellier, France-based pioneer in AI-driven genomic analysis, said it entered into a definitive agreement to acquire Cambridge, England-based Congenica, a company spun out of the Wellcome Sanger Institute.
SeqOne said the acquisition creates the largest global “software pure player” in the genomics space, serving over 160 labs in more than 30 countries.
“Founded in 2012, Congenica brings a legacy of deep clinical expertise and experience servicing over 25 private and public labs, including multiple NHS Genomics Laboratory Hubs and prestigious national programs such as Genomics England and the Hong Kong Genomic Program,” said SeqOne.
“SeqOne is an AI-powered genomic analysis platform, providing clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare and inherited diseases, and infectious diseases.
“The acquisition unites SeqOne’s AI-powered platform for Next-Generation Sequencing (NGS) analysis with Congenica’s trusted clinical decision support technology and clinical interpretation services.
“The integrated offering will transform complex genomic data into rapid, actionable insights, ultimately accelerating diagnosis for families affected by rare disease and enabling more precise, personalized cancer therapies.
“This move comes at a critical inflection point in medicine. The cost to sequence a human genome has plummeted, creating a data tsunami. For hospitals and labs worldwide, the challenge is no longer generating data, but interpreting it.
“This ‘interpretation bottleneck’ is the single biggest barrier to delivering personalized medicine, and it can only be solved with highly intelligent software.”
SeqOne CEO Martin Dubuc said: “The rapid pace of personalized medicine demands continuous investment in software innovation and deep specialization.
“By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
The acquisition comes on the heels of a period of intense organic growth for SeqOne which has seen the company double its revenue and expand its international presence from three to over 30 countries in 12 months.
It also follows the acquisition of Life & Soft in April, which expanded the company’s capabilities into multi-omics and virology. This momentum, boosted by a recent €20 million funding round from top-tier VCs, has enabled SeqOne to execute its strategy to consolidate a fragmented market and build the definitive software operating system for the clinical genomics revolution.
“The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception,” said Congenica chairman Andy Richards. “We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”